Uveitis Clinical Trial
The investigators hypothesize that it is safe and effective to treat patients with choroidal
neovascularisation (abnormal blood vessels growing under the retina) secondary to uveitis
with Conbercept.
This will be a randomized, placebo-controlled trial. 20 patients will receive three
injections of Conbercept into the affected eye (and repeated injections if required), and 20
patients will receive three sham injections requiring no needle stick, but making the
patient unaware of whether or not he received active treatment.
Outcome of the two treatment groups will be compared after one year.
Status | Not yet recruiting |
Enrollment | 40 |
Est. completion date | November 2018 |
Est. primary completion date | March 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patient with uveitis (without signs of active uveitis) related CNV, whatever the cause, including multifocal choroiditis, punctate inner choroidopathy, ocular toxoplasmosis, serpiginous choroiditis, Birdshot chorioretinopathy or VKH syndrome, etc, with active primary subfoveal, retrofoveal or juxtafoveal lesions that affect the fovea as evidenced by angiography and/or OCT in the studied eye - Total lesion area < 12 disc areas. - Total area of CNV within the lesion must be > 50% of total lesion. - Best corrected visual acuity of 20/40 to 20/320 in the study eye. - Willing and able to give informed consent. Exclusion Criteria: - Prior treatment in the study eye with, external-beam radiation therapy, subfoveal focal laser photocoagulation, vitrectomy, or transpupillary thermotherapy or other anti VEGF treatments, - History of submacular surgery or other surgical intervention in the study eye, glaucoma filtration surgery, corneal transplant surgery, - Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within one month preceding baseline, - Extracapsular extraction of cataract with phacoemulsification within three months preceding baseline, or a history of post-operative complications within the last 12 months preceding baseline in the study eye (uveitis, cyclitis, etc.), - History of uncontrolled glaucoma in the study eye (defined as intraocular pressure = 25 mmHg despite treatment with anti-glaucoma medication), - Aphakia with absence of the posterior capsule in the study eye, - Active intraocular inflammation (grade trace or above) in the study eye, - Any active infection involving ocular adnexa including infectious conjunctivitis, keratitis, scleritis, endophthalmitis, - Vitreous hemorrhage or history of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the study eye, - Presence of a retinal pigment epithelial tear involving the macula in the study eye, - Subfoveal fibrosis or atrophy in the study eye. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Chongqing Medical University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean Change in Best Corrected Visual Acuity (BCVA)Measured by Early Treatment Diabetic Retinopathy Study (ETDRS)at every visit | Compare of mean BCVA at every visit between the two groups to assess the efficacy of conbercept. | From Baseline to month 12 | No |
Secondary | Percentage of Participants Who Gained at Least 15/10/5 Letters in BCVA as Measured by ETDRS at month 12 | Baseline, month 12 | No | |
Secondary | Percentage of Participants Who Gained at Least 15/10/5 Letters in BCVA as Measured by ETDRS at month 6 | Baseline, month 6 | No | |
Secondary | Percentage of Participants Who Lost at Least 15/10/5 Letters in BCVA Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) at month 6 | Baseline, month 6 | No | |
Secondary | Percentage of Participants Who Lost at Least 15/10/5 Letters in BCVA Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) at month 12 | Baseline, month 12 | No | |
Secondary | Mean Change in Central Retinal Thickness (CRT) as Assessed by Optical Coherence Tomography (OCT) at every visit | 12 months | No | |
Secondary | Mean Change in Choroidal Neovascularization (CNV) Lesion Size as Assessed by Fluorescein Angiography (FA) From Baseline to month 3/6/12 | Baseline, month 3, 6 and 12 | No | |
Secondary | Mean Change in European Five-dimensional Health Scale (EQ-5D) Score From Baseline to month 12 | Baseline, month 12 | No | |
Secondary | Mean Change in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score From Baseline to month 12 | Baseline, month 12 | No | |
Secondary | Mean Change in Area of Leakage assessed by FFA From Baseline at month 3\6\12 | Baseline, month 3, 6 and 12 | No | |
Secondary | Number of participants with adverse events | Compare of Number of participants with adverse events between the two groups to assess the safety of conbercept | 12 months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101604 -
Biomarkers of Common Eye Diseases
|
||
Active, not recruiting |
NCT04704609 -
Imaging Quantification of Inflammation (IQI)
|
||
Completed |
NCT03173144 -
Chronic Inflammatory Disease, Lifestyle and Treatment Response
|
||
Withdrawn |
NCT01280669 -
Intravitreal Sirolimus as Therapeutic Approach to Uveitis
|
Phase 2 | |
Terminated |
NCT02907814 -
Measurement of Anterior Chamber Cell Grading Using Ocular Coherence Tomography
|
N/A | |
Active, not recruiting |
NCT02252328 -
Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients
|
Phase 2/Phase 3 | |
Completed |
NCT04183387 -
Simvastatin in Uveitis
|
Phase 2 | |
Completed |
NCT01983488 -
Clinical Outcome in Uveitis
|
||
Withdrawn |
NCT00499551 -
A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis
|
Phase 1/Phase 2 | |
Terminated |
NCT00114062 -
Study to Treat Uveitis Associated Macular Edema
|
Phase 2 | |
Completed |
NCT00476593 -
Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications
|
N/A | |
Completed |
NCT00132691 -
Multicenter Uveitis Steroid Treatment (MUST) Trial
|
Phase 4 | |
Completed |
NCT00001867 -
Effect of Pregnancy on Uveitis
|
N/A | |
Completed |
NCT00379275 -
Eye and Immunogenetic Features of Sarcoidosis
|
N/A | |
Active, not recruiting |
NCT03828019 -
Adalimumab vs. Conventional Immunosuppression for Uveitis Trial
|
Phase 3 | |
Terminated |
NCT01939691 -
Macular Edema Nepafenac vs. Difluprednate Uveitis Trial
|
Phase 4 | |
Active, not recruiting |
NCT03889860 -
Objective Choroidal Thickness Measurements in Uveitis
|
||
Completed |
NCT00070759 -
Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis
|
Phase 2 | |
Recruiting |
NCT05486468 -
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
|
Phase 3 | |
Active, not recruiting |
NCT05385757 -
UNICORNS: Uveitis in Childhood Prospective National Cohort Study
|